

Collaborating for innovation



An exciting new alliance has been announced between Sanofi and Oxford University Medical Sciences Division.

The partnership is focussed on seeding, catalysing and executing biomedical innovation.

The goal is to generate new therapeutic or technological projects utilising Oxford's emerging science in partnership with the world-leading pharmaceutical company. Sanofi will provide financial, translational and commercial support to shape projects from Oxford and work closely with the medical sciences team in Oxford to identify novel and breakthrough biology.

Peter Hamley, Head of Drug Discovery Technology Platforms, Global Business Development & Licensing at Sanofi, said "Oxford is a world leader in bioscience innovation and this alliance will help us to access exciting science from Oxford's large ecosystem".

Professor Matthew Wood, Deputy Head of the Medical Sciences Division (Innovation) of Oxford University Medical Sciences said "working closely with Sanofi will lead to new collaborations and more opportunities for Oxford research to be turned into therapies or technologies for the benefit of patients".

Dr Hubert Bland, Medical Director of Sanofi UK said 'This is a great example of partnership between a pharmaceutical company and

"Oxford is a world leader in bioscience innovation and this alliance will help us to access exciting science from Oxford's large ecosystem."



Peter Hamley
Head of Drug Discovery
Technology Platforms,
Global Business Development &
Licensing, **Sanofi**

academia which has the opportunity to facilitate collaboration, sharing of expertise and knowledge and ultimately provide innovative medicines which could make a real difference. Sanofi UK is delighted to be able to work in this way with the University of Oxford.'

The partnership has been signed for an initial three years and also provides the opportunity to arrange exchange between the scientists of each respective organisation.



UNIVERSITY OF
OXFORD

